Browse SH3BP2

Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF00169 PH domain
PF00017 SH2 domain
Function

Binds differentially to the SH3 domains of certain proteins of signal transduction pathways. Binds to phosphatidylinositols; linking the hemopoietic tyrosine kinase fes to the cytoplasmic membrane in a phosphorylation dependent mechanism.

> Gene Ontology
 
Biological Process -
Molecular Function GO:0005070 SH3/SH2 adaptor activity
GO:0017124 SH3 domain binding
GO:0030674 protein binding, bridging
GO:0035591 signaling adaptor activity
GO:0060090 binding, bridging
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04650 Natural killer cell mediated cytotoxicity
Reactome -
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between SH3BP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between SH3BP2 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
29885053Gastrointestinal Stromal TumorInhibit immunityOur current study shows that SH3BP2 is expressed in primary tumors and cell lines from GIST patients and that SH3BP2 silencing leads to a downregulation of oncogenic KIT and PDGFRA expression and an increase in apoptosis in imatinib-sensitive and -resistant GIST cells. Furthermore, SH3BP2 silencing significantly reduces cell migration and tumor growth of imatinib-sensitive and resistant cells in vivo.
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of SH3BP2 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of SH3BP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.140.487
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.0280.984
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2260.818
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.2050.554
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4540.849
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1140.971
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0960.795
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0490.976
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2730.882
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6870.675
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1770.623
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1080.195
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of SH3BP2 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59200200.357
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 512200200.294
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SH3BP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SH3BP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SH3BP2.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SH3BP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of SH3BP2 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between SH3BP2 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolSH3BP2
NameSH3-domain binding protein 2
Aliases RES4-23; CRBM; Cherubism; 3BP-2; 3BP2; CRPM; Abl-SH3 binding protein 2; SH3 domain-binding protein 2
Chromosomal Location4p16.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting SH3BP2 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.